Price Chart
Key Statistics
Previous Close
$37.35Day Range
52-Week Range
Avg Volume
5.3KDividend Yield
—Expense Ratio
0.35%AUM
$1.3MShares Outstanding
54.7KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 95.25% |
| Cash & Others | 2.52% |
| Technology | 2.23% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 89.69% |
| Denmark | 3.04% |
| Netherlands | 2.77% |
| Other | 2.62% |
| Switzerland | 1.88% |
Fund Information
- Issuer
- Corgi Funds
- Category
- Healthcare
- Inception Date
- May 5, 2026
- Description
- GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Similar ETFs
The Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF (GNMX) is an exchange-traded fund issued by Corgi Funds that launched on May 5, 2026. It currently manages $1.3M in assets under management. The fund charges an expense ratio of 0.35%. The fund holds 30 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 48.6% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | MRNA | Moderna Inc | 10.54% | 581 | $137K |
| 2 | TMO | Thermo Fisher Scientific Inc | 8.98% | 168 | $117K |
| 3 | VRTX | Vertex Pharmaceuticals Inc | 5.74% | 147 | $75K |
| 4 | ILMN | Illumina Inc | 4.75% | 231 | $62K |
| 5 | GH | Guardant Health Inc | 3.47% | 273 | $45K |
| 6 | IOVA | Iovance Biotherapeutics Inc | 3.22% | 2,849 | $42K |
| 7 | RVMD | Revolution Medicines Inc | 3.15% | 217 | $41K |
| 8 | TXG | 10X Genomics Inc | 3.15% | 567 | $41K |
| 9 | GMAB | Genmab A/S | 3.09% | 1,064 | $40K |
| 10 | INCY | Incyte Corp | 2.55% | 294 | $33K |
| 11 | — | First American Government Obligations Fund 12/01/2031 | 2.55% | 33,206 | $33K |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | 2.51% | 140 | $33K |
| 13 | TWST | Twist Bioscience Corp | 2.41% | 217 | $31K |
| 14 | GRAL | GRAIL Inc | 2.18% | 210 | $28K |
| 15 | TECH | Bio-Techne Corp | 2.14% | 385 | $28K |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +1.98% | |
| 1W | +3.91% | |
| 1M | +1.10% | |
| 3M | +27.54% | |
| 6M | +47.60% | |
| YTD | +47.60% | |
| 1Y | +47.60% | |
| 3Y | +47.60% | |
| 5Y | +47.60% |
Moving Averages
$37.29
Above 20-Day MA$35.92
Above 50-Day MA$18.56
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$39.20
Current Price
$38.09
52-Week Low
$24.02
Current Yield
—
Annual Dividend
—
Frequency
—
Last Ex-Date
—
Dividends
No dividend data available for this ETF.
Category Comparison
| Metric | GNMX | Healthcare(205 ETFs) |
|---|---|---|
| Fund Info | ||
| Expense Ratio | 0.35% | 0.64% |
| AUM | $1.3M | $868.4M |
| Dividend Yield | — | 4.50% |
| Avg Volume | 5.3K | 264.1K |
| Holdings | 30 | 145 |
| Performance | ||
| 1-Month Return | +1.10% | -1.96% |
| 6-Month Return | +57.97% | +10.01% |
| YTD Return | — | +11.25% |
| 1-Year Return | — | +7.17% |
Compare with Another ETF
Search for an ETF to compare with GNMX:
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.